The company reported a profit of $317.1 million for the quarter, rising from $274.6 million during the same period last year. Earnings reached $4.01 a share, comfortably beating the $3.73 estimate anticipated by analysts. Revenue climbed 10% to $1.21 billion, exceeding the $1.19 billion forecast.
In section Market Quotes
Idexx Laboratories Shares Rally Following Upbeat Quarterly Results
Shares of Idexx Laboratories surged 18% to $651.88 on Monday, as the pet-healthcare firm surpassed Wall Street expectations with a strong third-quarter performance and an upward revision of its annual financial guidance.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2212289374-64be8a37ce6b42c8b7298c8074118732.jpg)
Following these results, management raised its annual earnings outlook to a range of $14.96 to $15.16 a share, up from the previous projection of $14.69 to $14.94. Annual revenue is now expected to hit $4.74 billion to $4.77 billion, topping earlier estimates of $4.7 billion to $4.75 billion. Chief Executive Mike Erickson credited the performance to consistent commercial execution and the company's focus on innovation-driven growth.
Comments (0)
No comments yet. Be the first!